Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease

The extent to which newly developed blood-based biomarkers could reduce screening costs in secondary prevention trials of Alzheimer’s disease is mostly unexplored. We collected plasma amyloid-β42/40, apolipoprotein E ε4 status and amyloid PET at baseline in 181 cognitively unimpaired participants [t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullen, Nicholas C, Janelidze, Shorena, Stomrud, Erik, Bateman, Randall J, Palmqvist, Sebastian, Hansson, Oskar, Mattsson-Carlgren, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012324/
https://www.ncbi.nlm.nih.gov/pubmed/36926368
http://dx.doi.org/10.1093/braincomms/fcad015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012324/
https://www.ncbi.nlm.nih.gov/pubmed/36926368
http://dx.doi.org/10.1093/braincomms/fcad015

Ejemplares similares